Eltrombopag olamine

Details

Files

Generic Name:

Eltrombopag olamine

Project Status:

Complete

Therapeutic Area:

Chronic immune thrombocytopenic purpura

Manufacturer:

GlaxoSmithKline

Call for patient/clinician input open:

April 26, 2011

Brand Name:

Revolade

Project Line:

Reimbursement Review

Project Number:

SR0230-000

Call for patient/clinician input closed:

May 17, 2011

NOC Status at Filing:

Post NOC

Submission Type:

Initial

Indications:

Thrombocytopenic purpura chronic immune (idiopathic)

Recommendation Type:

Do not list

Final Recommendation:

October 24, 2011

Last Updated : April 26, 2011